Safety Study of Replagal® Therapy in Children With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Fabry Disease
Related studies linked through entity extraction aliases.
Home Therapy With Replagal in Fabry Disease
- Status
- COMPLETED
- Phase
- N/A
Pulmonary Disease and Exercise Tolerance in Boys With Fabry Disease
- Status
- UNKNOWN
- Phase
- N/A
This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.
- Status
- COMPLETED
- Phase
- PHASE2
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE3
Androgenetic Alopecia in Fabry Disease
- Status
- COMPLETED
- Phase
- N/A
The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease
- Status
- COMPLETED
- Phase
- N/A
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE3
Sophisticated Assessment of Disease Burden in Patients With Fabry Disease
- Status
- COMPLETED
- Phase
- N/A
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE2
Establishment of Biomarkers for Fabry Disease
- Status
- COMPLETED
- Phase
- N/A
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE3
Treatment Protocol of Replagal for Patients With Fabry Disease
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Fabry Screening Study
- Status
- COMPLETED
- Phase
- N/A
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE3
Viennese Prevalence Study of Anderson-Fabry Disease
- Status
- UNKNOWN
- Phase
- N/A
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE3
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
- Status
- COMPLETED
- Phase
- PHASE3
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
- Status
- TERMINATED
- Phase
- PHASE2